These therapies can deliver localised radiation to tumours with reduced systemic exposure, representing a significant advancement in targeted medicine, reports Silje Sivesind, Sector Director Operations at Agilera Pharma AS.
Unlike conventional drugs, radiopharmaceuticals operate within constraints imposed by radioactive decay and strict safety protocols.
As such, they require fundamentally different approaches to development, manufacturing and distribution that eliminate traditional stockpiling and leave no margin for delays.
These constraints have led many developers to partner with specialised contract development and manufacturing organisations (CDMOs) that possess the infrastructure and expertise to navigate the unique requirements of radiopharmaceuticals.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.